Clinical Trial

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

Name: Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients — clinical trial record (NCT07620561)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Trial Details

NCT Number	NCT07620561
Lead Sponsor	University of Maryland, Baltimore Collaborators: Eli Lilly and Company
Conditions	Prurigo Nodularis (PN)
Enrollment	15 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-02